Chances are 50-50; it is not that data is going to be bad. Question is - is it going to be good enough to make headlines on Wall Street that will have BP companies lining up to make deals with ADXS, either in the form of a BO or some real good partnerships that will benefit shareholders.
To date ADXS has not impressed anyone for whatever reason - be it management messing up, wasting time and precious resources, or for what one may call damn luck. The company has nothing to show for their Osteo Sarcoma venture or that India trial; While they are enrolling patients in a multitude of trials with various agencies and companies involved, there is no news on progress or an update. To me it seems, they are into too many trials, thanks to money raised in millions, there is lot of hiring and building of facilities etc. as we wait eternal for data.
Question for you - Do you think that we will have data that will have major TV networks going gaga over ADXS? We were once leaders in immunotherapy, when were were not even listed on the major stock exchange ( and that was years ago) and now we are laggards.
We will soon know - another year at most or some may say another 2 years when it will all unfold. Data will speak louder than any post here, including mine.
Market Data 
Markets 
AI
